Sremac, M., Paić, F., Ravić, K., Šerman, Lj., Pavičić Dujmović, A., Brčić, I. ... Martić, T. (2021). Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma. Oncology Letters, 22. (6). doi: 10.3892/ol.2021.13083
Sremac, Maja, et al. "Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma." Oncology Letters, vol. 22, no. 6, 2021. https://doi.org/10.3892/ol.2021.13083
Sremac, Maja, Frane Paić, Katja Ravić, Ljiljana Šerman, Aja Pavičić Dujmović, Iva Brčić, Željko Krznarić and Tamara Martić. "Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma." Oncology Letters 22, no. 6 (2021). https://doi.org/10.3892/ol.2021.13083
Sremac, M., et al. (2021) 'Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma', Oncology Letters, 22(6). doi: 10.3892/ol.2021.13083
Sremac M, Paić F, Ravić K, Šerman Lj, Pavičić Dujmović A, Brčić I, and sur.. Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma. Oncology Letters [Internet]. 2021 October 08 [cited 2024 December 30];22(6). doi: 10.3892/ol.2021.13083
M. Sremac, et al., "Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma", Oncology Letters, vol. 22, no. 6, October 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:791452. [Accessed: 30 December 2024]